Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
Walker, D.P., Bi, F.C., Kalgutkar, A.S., Bauman, J.N., Zhao, S.X., Soglia, J.R., Aspnes, G.E., Kung, D.W., Klug-McLeod, J., Zawistoski, M.P., McGlynn, M.A., Oliver, R., Dunn, M., Li, J.C., Richter, D.T., Cooper, B.A., Kath, J.C., Hulford, C.A., Autry, C.L., Luzzio, M.J., Ung, E.J., Roberts, W.G., Bonnette, P.C., Buckbinder, L., Mistry, A., Griffor, M.C., Han, S., Guzman-Perez, A.
Bioorg.Med.Chem.Lett.
